50
Participants
Start Date
July 11, 2020
Primary Completion Date
July 27, 2023
Study Completion Date
February 13, 2028
Abemaciclib
100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
LY3214996
400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
St. Joseph's Hospital and Medical Center, Phoenix
Chandler Regional Medical Center, Chandler
HonorHealth Scottsdale Osborn Medical Center, Scottsdale
Barrow Neurological Institute
OTHER
Ivy Brain Tumor Center
OTHER
Eli Lilly and Company
INDUSTRY
Nader Sanai
OTHER